Last reviewed · How we verify

Peripheral vascular disease — Treatment Landscape & Competitive Intelligence

Peripheral vascular disease (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Peripheral vascular disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Brilinta ticagrelor AstraZeneca P2Y12 Platelet Inhibitor [EPC] Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12
Brilinta Brilinta AstraZeneca Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Peripheral vascular disease
  2. AstraZeneca · 2 drugs in Peripheral vascular disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Peripheral vascular disease:

Cite this brief

Drug Landscape (2026). Peripheral vascular disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/peripheral-vascular-disease. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing